


# Mapracorat

10/20

**ALTERNATE NAMES:** BOL-303242X; ZK-245186; (2R)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-4-methyl-2-[[[2-methylquinolin-5-yl]amino]methyl]pentan-2-ol; 7-Benzofuranpropanol, 5-fluoro-2,3-dihydro-gamma,gamma-dimethyl-alpha-(((2-methyl-5-quinolinyl)amino)methyl)-alpha-(trifluoromethyl)-, (alphaR)-

**CATALOG #:** B3078-1 1 mg  
B3078-5 5 mg

**STRUCTURE:**



**MOLECULAR FORMULA:** C<sub>25</sub>H<sub>26</sub>F<sub>4</sub>N<sub>2</sub>O<sub>2</sub>

**MOLECULAR WEIGHT:** 462.49

**CAS NUMBER:** 887375-26-0

**APPEARANCE:** Yellow crystals

**PURITY:** >98%

**SOLUBILITY:** ~33 mg/ml in DMSO

**DESCRIPTION:** Mapracorat is a selective glucocorticoid receptor agonist (SEGRA) with anti-inflammatory properties. It is in clinical trials for the topical treatment of atopic dermatitis, allergic conjunctivitis and Eczema. It inhibits TNF $\alpha$  secretion from activated canine peripheral blood derived mononuclear cells with an IC<sub>50</sub> value of approximately 0.2 nM. It shows beneficial effects in inflammatory and pruritic skin diseases in dogs.

**STORAGE TEMPERATURE:** -20°C

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**REFERENCE:** Baumer, W., Rossbach, K., Schmidt, B.H. The selective glucocorticoid receptor agonist mapracorat displays a favourable safety-efficacy ratio for the topical treatment of inflammatory skin diseases in dogs. *Vet Dermatol* 28(1):46-e11 (2017).

**RELATED PRODUCTS:**

Budesonide (Cat. No. 2773)  
 Demethoxycurcumin (Cat. No. B2945)  
 Withaferin A (Cat. No. B2716)  
 Triamcinolone acetonide (Cat. No. B1520)  
 Dexamethasone (Cat. No. 1042)

**DISCLAIMER:** **FOR RESEARCH USE ONLY! Not to be used on humans.**